US 12,152,067 B2
Human antibodies to ebola virus glycoprotein
Christos Kyratsous, Irvington, NY (US); William Olson, Yorktown Heights, NY (US); Peter Mason, Somerville, MA (US); and Neil Stahl, Carmel, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Nov. 9, 2022, as Appl. No. 18/053,927.
Application 15/688,474 is a division of application No. 15/005,334, filed on Jan. 25, 2016, granted, now 9,771,414, issued on Sep. 26, 2017.
Application 18/053,927 is a continuation of application No. 17/039,557, filed on Sep. 30, 2020, granted, now 11,530,255.
Application 17/039,557 is a continuation of application No. 16/663,261, filed on Oct. 24, 2019, granted, now 10,829,544, issued on Nov. 10, 2020.
Application 16/663,261 is a continuation of application No. 16/108,096, filed on Aug. 22, 2018, granted, now 10,501,526, issued on Dec. 10, 2019.
Application 16/108,096 is a continuation of application No. 15/688,474, filed on Aug. 28, 2017, granted, now 10,081,670, issued on Sep. 25, 2018.
Claims priority of provisional application 62/245,703, filed on Oct. 23, 2015.
Claims priority of provisional application 62/161,356, filed on May 14, 2015.
Claims priority of provisional application 62/107,581, filed on Jan. 26, 2015.
Prior Publication US 2024/0327501 A1, Oct. 3, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/10 (2006.01); A61K 39/12 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/10 (2013.01) [A61K 39/3955 (2013.01); A61K 2039/507 (2013.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 57 Claims
 
1. A method of neutralizing infectious Ebola virus (EBOV), the method comprising exposing a cell infected with EBOV to a composition comprising three anti-EBOV antibodies or antigen-binding fragments thereof, wherein:
(a) a first anti-EBOV antibody or antigen-binding fragment thereof comprises a heavy chain complementarity determining region 1 (HCDR1) amino acid sequence as set forth in SEQ ID NO: 20 with no more than one amino acid substitution; an HCDR2 amino acid sequence as set forth in SEQ ID NO: 22 with no more than one amino acid substitution; an HCDR3 amino acid sequence as set forth in SEQ ID NO: 24 with no more than one amino acid substitution; a light chain complementarity determining region LCDR1 amino acid sequence as set forth in SEQ ID NO: 28 with no more than one amino acid substitution; an LCDR2 amino acid sequence as set forth in SEQ ID NO: 30 with no more than one amino acid substitution; and an LCDR3 amino acid sequence as set forth in SEQ ID NO: 32 with no more than one amino acid substitution;
(b) a second anti-EBOV antibody or antigen-binding fragment thereof comprises an HCDR1 amino acid sequence of SEQ ID NO: 68 with no more than one amino acid substitution; an HCDR2 amino acid sequence of SEQ ID NO: 70 with no more than one amino acid substitution; an HCDR3 amino acid sequence of SEQ ID NO: 72 with no more than one amino acid substitution; an LCDR1 amino acid sequence of SEQ ID NO: 76 with no more than one amino acid substitution; an LCDR2 amino acid sequence of SEQ ID NO: 78 with no more than one amino acid substitution; and an LCDR3 amino acid sequence of SEQ ID NO: 80 with no more than one amino acid substitution; or
(c) a third anti-EBOV antibody or antigen-binding fragment thereof comprises an HCDR1 amino acid sequence of SEQ ID NO: 148 with no more than one amino acid substitution; an HCDR2 amino acid sequence of SEQ ID NO: 150 with no more than one amino acid substitution; an HCDR3 amino acid sequence of SEQ ID NO: 152 with no more than one amino acid substitution; an LCDR1 amino acid sequence of SEQ ID NO: 156 with no more than one amino acid substitution; an LCDR2 amino acid sequence of SEQ ID NO: 158 with no more than one amino acid substitution; and an LCDR3 amino acid sequence of SEQ ID NO: 160 with no more than one amino acid substitution.